C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab-Reference-Cited by-同舟云学术

C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab

Published:2020-09-11 Issue:11 Volume:95 Page:1334-1343
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Castro Carlos¹,Grossi Federico²,Weitz Ilene Ceil³,Maciejewski Jaroslaw⁴,Sharma Vivek⁵,Roman Eloy⁶,Brodsky Robert A.⁷,Tan Lisa⁸,Di Casoli Carl²,El Mehdi Delphine²,Deschatelets Pascal²,Francois Cedric²

Affiliation:

1. Duke University School of Medicine Durham North Carolina USA

2. Apellis Pharmaceuticals Waltham Massachusetts USA

3. Keck School of Medicine of USC Los Angeles California USA

4. Translational Hematology and Oncology Research Taussig Cancer Institute Cleveland Ohio USA

5. University of Louisville Louisville Kentucky USA

6. Lakes Research Miami Lakes Florida USA

7. Johns Hopkins University School of Medicine Baltimore Maryland USA

8. Lisa Tan Pharma Consulting Ltd Cambridge UK

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25960

Reference28 articles.

1. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria

2. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene.

3. Resistance of Paroxysmal Nocturnal Hemoglobinuria Cells to the Glycosylphosphatidylinositol-Binding Toxin Aerolysin

4. Complement System Part I â€“ Molecular Mechanisms of Activation and Regulation

5. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complement C3 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with suboptimal response to C5 inhibitor therapy;Oncohematology;2024-09-01

2. Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors;International Journal of Molecular Sciences;2024-08-31

3. Three Years On: The Role of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) since Its Initial Approval;International Journal of Molecular Sciences;2024-08-09

4. CG001, a C3b-targeted complement inhibitor, blocks 3 complement pathways: development and preclinical evaluation;Blood Advances;2024-08-02

5. Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors;PLOS ONE;2024-07-29